Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Learn more about the OPuS One clinical trial, a post-market study for OsteoCool™ radiofrequency ablation.
OPuS One: Outcomes from 206 patients treated with up to 12 months follow-up.
OPuS One: Published primary manuscript from first 100 patients treated.
The OsteoCool Post-Market Study, “OPuS One,” is a prospective multicenter study in the United States, Europe, and Canada. The goal of the study is to collect real-world outcomes on effectiveness and safety among a cohort of patients who have been treated with the OsteoCool™ RF ablation system.
OBJECTIVES OF THE 12-MONTH ANALYSIS:
POST PROCEDURE FOLLOW-UP:
Levy J, Hopkins T, Morris J, et al. Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. J Vasc Interv Radiol 2020; 31:1745–1752. https://doi.org/10.1016/j.jvir.2020.07.014
Levy J, David E, Hopkins T, et al. Radiofrequency Ablation for the Palliative Treatment of Osseous Metastases: Final Results from a Multicenter Study (OPuS One). Abstract at Society for Interventional Radiology Annual Scientific Meeting 2021.
Levy J, David E, Hopkins T, et al. Improvement In Quality Of Life In Patients Treated For Painful Osseous Metastases With Radiofrequency Ablation: The Opus One Study. Abstract at Society for Interventional Radiology Annual Scientific Meeting 2021.